← Back to list
Strensiq (asfotase alfa)
Act
by Jun 1, 2025
Effective date
Jun 1, 2025
Identified
Jun 20, 2026
Summary
BCBS Mississippi updated their prior authorization policy for Strensiq (asfotase alfa), a rare disease medication for hypophosphatasia, with revised medical necessity criteria and new renewal requirements effective June 1, 2025.
Get alerts when payers change rules like this one
We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.
What to do
by Jun 1, 2025 · 3 steps
01Update prior authorization protocols for Strensiq (asfotase alfa) to reflect new medical necessity criteria requiring ophthalmology examination and renal ultrasound at baseline, active disease documentation, and clinical manifestations prior to age 18.
02Update renewal criteria to require documented clinical improvement in respiratory status, growth, radiographic findings, or activity level.
03Train staff on revised criteria as this affects rare pediatric cases with hypophosphatasia.
Codes mentioned
C9399J3590
Original notice
Strensiq (asfotase alfa)
bcbsms.com · Always check the source before changing claims.
Related changes
See all Blue Cross & Blue Shield of Mississippi changes →Dupixent (dupilumab)MediumEffective Oct 1, 2025 · Medical PolicyAgents for Recurrent Clostridioides DifficileMediumNo effective date · Medical PolicyState and School Employees' Health Insurance Plan - Multiple SclerosisMediumNo effective date · Medical PolicyMultiple SclerosisMediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list